Cara Therapeutics, Inc.
4 Stamford Plaza
107 Elm Street, 9th Floor
Stamford, Connecticut 06902
May 9, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Michael Davis | |
| Re: | Cara Therapeutics, Inc. | |
| Registration Statement on Form S-3 (File No. 333-263165), as amended by Amendment No. 1 | ||
|
Request for Acceleration of Effective Date | ||
| Acceleration Request | |||
| Requested Date: | May 11, 2022 | ||
| Requested Time: | 4:00 p.m. Eastern Time |
Mr. Davis:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-263165), as amended by Amendment No. 1 (the “Registration Statement”) to become effective on May 11, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034.
[Signature page follows]
| Very truly yours, | ||
| Cara Therapeutics, Inc. | ||
| By: |
/s/ Christopher Posner | |
| Christopher Posner | ||
| Chief Executive Officer and Director | ||
|
cc: Christopher Posner, Cara Therapeutics, Inc. Darren DeStefano, Cooley LLP
|
Signature Page to Company Acceleration Request – S-3